Pressure Continues for TPP to Include Biologic Exclusivity

As the Trans-Pacific Partnership (TPP) talks head into their 14th round early next month, U.S. lawmakers continue to press the president to ensure the negotiations protect the 12-year data exclusivity for biologics.

Such protection is needed for U.S. biotechs to compete on a level playing field and to safeguard the health of the nation's life sciences industry, Sen. Claire McCaskill (D-Mo.) said in a recent letter to the president.